BBIO vs EXEL
BridgeBio Pharma, Inc. and Exelixis, Inc., both Healthcare
Exelixis, Inc. is the larger company at $13B against $13B. Over the past year BBIO returned +73% against +50% for EXEL. Ryufin's sector-relative Smart Score puts EXEL ahead, 8/10 against 3/10.
| Figure | BBIO | EXEL |
|---|---|---|
| Last close | $79.36 | $56.07 |
| Market cap | $13B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 18.6 |
| 1-year return | +73% | +50% |
| 5-year return | +52% | +225% |
| Ryufin Smart Scoresector-relative, 1–10 | 3/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Exelixis, Inc.
Revenue of $611M in Q1 2026, net income $210M. Its largest reported line is Product Gross, 87% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.